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Background: Streptococcus pneumoniae is the leading cause of community-acquired pneumonia in the elderly, and 
in recent years it has arisen as an important pathogen in HIV-infected patients. However, there is a scarcity of 
information on clinical and therapeutic problems associated with pneumococcal infections in other immuno- 
compromised patients. The objective of this study was to assess the most relevant epidemiologic aspects, clinical 
features and prognostic factors of pneumococcal bacteremia in immunocompromised hosts without AIDS. 
Methods: This was a retrospective analysis of patients with pneumococcemia, carried out in a 600-bed, university- 
affiliated hospital in Madrid, Spain, Two-hundred and sixty patients were evaluated retrospectively; 69 (26.5%) 
immunocompromised patients based on strict case definitions were compared with a group composed of 191 non- 
immunocompromised hosts with a variety of chronic conditions. Conventional management of pneumococcal 
bacteremia according to clinical standards was assessed. The MICs of penicillin and other p-lactam antibiotics, and 
related mortality and hospital mortality at 30 days, were measured. 
Results: A comparison of clinical manifestations of pneumococcemia between immunocompromised patients and 
non-immunocompromised patients did not show differences in the presence of fever, obtundation, type of lung 
involvement, frequency of primary bacteremia, or meningitis. Hospital-acquired pneumococcemia was significantly 
more frequent in immunocompromised patients (34.7% versus 6.8%, P<O.OOOl), and resistance to penicillin was also 
more common in pneumococcal strains isolated from these patients (37.5% versus 20%, P=O.O009). Septic shock 
occurred more frequently in immunocompromised patients, although the overall and related mortality were not 
significantly different from those found in non-immunocompromised patients (33.3% versus 22.5%, P=O.O7, and 
28.9% versus 20.9%, P=O.7 respectively). In the multivariate analysis, multilobar pneumonia (odds ratio (OR) 15.7; 
95% CI 6.0041.30; P<O.OOl), inadequate treatment (OR 12.20; 95% CI 4.10-37.20; P<O.OOl), obtundation (OR 5.80; 
95% CI 2.20-15.00; P<O.OOl) and hospital-acquired bacteremia (OR 4.80; 95% CI 1.00-14.60; P<O.O06) were 
associated with an increased risk of mortality in patients with pneumococcemia. Only multilobar pneumonia (OR 
7.90; 95% CI 4.10-15.35; P<O.OOl) was significantly associated with an increased risk of mortality in immuno- 
compromised patients. Patients with acute leukemia and lymphoma had a greater mortality rate than non- 
immunocompromised patients (53.8% related mortality, P=O.O5). Analysis of these patients showed frequent 
inadequate empirical therapy with ceftazidime plus amikacin in the presence of p-lactam resistance. 
Conclusions: Much of the burden of pneumococcal bacteremia was attributable to immunosuppressive diseases. In 
immunocompromised patients, pneumococcemia was frequently acquired within the hospital during the treatment 
of the underlying condition, and resistance to penicillin was common. Patients with acute leukemia and lymphoma 
who develop fever and pneumonia should be treated with drugs active against P-lactam-resistant pneumococci, 
irrespective of the setting in which the infection develops. 
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Streptococcus pneumoniae is the leading etiologic 
pathogen of bacterial meningitis and pneumonia in 
adults, and continues to be an important cause of 
morbidity and mortality. I,* Although pneumococcal 
infections are common in the normal aged population 
as community-acquired infections3 they also occur in 
a wide variety of immunocompromised patients, and 
occasionally they have been found as nosocomial in- 
fections.4*s 
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In the last two decades, several reports have focused 
on pneumococcal bacteremia and pneumonia in patients 
with AIDS.6,7 However, there is a scarcity of information 
in the most recent literature on clinical and prognostic 
aspects of pneumococcal infection in other immuno- 
compromised patients without AIDS.8~9 In this investiga- 
tion, we tried to assess the most relevant epidemiologic 
findings, clinical manifestations and risk factors for 
mortality of a large series of immunocompromised hosts 
with S. pneumoniae bacteremia. We were particularly 
interested in looking at the impact of resistance to /3- 
lactam antibiotics on the outcome of patients. 
PATIENTS AND METHODS 
We have retrospectively reviewed the clinical and 
microbiological records of patients with pneumococcal 
bacteremia (one or more positive blood cultures) studied 
over a period of 18 years (January 1981 to December 
1998) in Fundacidn Jimknez Diaz, a 600-bed hospital, 
associated with the Universidad Aut6noma de Madrid, 
Spain. Most patients had been seen by members of the 
Division of Infectious Disease as part of a prospective 
study of bacteremia. 
A patient was defined as an ‘immunocompromised 
host’ when he had a previous diagnosis of hematologic 
neoplasia (acute leukemia or lymphoma under chemo- 
therapy), congenital or acquired defects of humoral 
immunity (agammaglobulinemia, chronic lymphocytic 
leukemia, or multiple myeloma), or solid tumors on 
chemotherapy and/or radiotherapy, or had received high- 
dose, non-physiologic corticosteroid therapy (>20 mg 
prednisone/day) for at least 4 weeks. As a group, these 
patients were compared with non-immunocompromised 
patients seen during the same period. Patients with 
chronic diseases such as cardiomyopathy, obstructive 
lung disease, cirrhosis of the liver and diabetes mellitus 
were included within this group. 
The identification of S. pneumoniae from com- 
mercial blood cultures (HCmoline Performance DUO, 
bioMerieux, Mercy-L’Etoile, France) was done follow- 
ing previously published procedures.‘” All strains were 
initially screened for susceptibility to antimicrobial 
agents by means of the disk diffusion method on 
Mueller-Hinton blood agar plates.” A l-kg oxacillin 
disk was used to detect all strains with decreased 
susceptibility to penicillin. In addition, susceptibility 
testing was performed with the use of an agar dilution 
method as described by Washington and Sutter.12 An 
isolate was defined as penicillin susceptible when 
the MIC of penicillin was <O.l kg/mL, intermediately 
resistant when the MIC was between 0.1 mg/mL and I 
mg/mL, and resistant when the MIC was greater than I 
mg/mL.‘” Strains with MICs for ceftazidime >2 kg/mL 
were considered to be resistant. 
The infection was ‘community-acquired’ when 
clinical symptoms were present on admission, and the 
positive blood cultures were taken in the emergency 
room or within 24 h of hospitalization. The infection 
was ‘hospital-acquired’ when clinical and radiologic 
manifestations developed after 3 or more days of 
hospitalization, and the blood cultures which were 
reported positive were drawn after 72 h of admission.14 
Pneumonia was defined by a compatible clinical picture 
plus alveolar infiltrates involving only one lobe of the 
lung. Multilobar pneumonia was that in which two or 
more pulmonary lobes were involved. 
Treatment was considered ‘adequate’ when patients 
were given three or more doses of antibiotics active 
against the isolate by in vitro testing. Therapy was con- 
sidered ‘inadequate’ when the isolate showed in vitro 
resistance to the antibiotics given to the patient, or, due 
to the fulminant evolution of the infection, less than 
three doses were administered. 
Mortality was defined as ‘infection-related’ when 
the patient died within 10 days of the beginning of 
the clinical picture in the absence of other obvious 
causes. Overall hospital mortality was the mortality that 
occurred within 30 days after hospitalization. 
The x2 test or Fisher’s exact test were used when 
appropriate for categorical variables. A P-value of co.05 
was considered statistically significant. Logistic regression 
analysis was also performed for all significant variables 
associated with mortality by using the Cox-Mantel test. 
RESULTS 
From January 1980 to December 1998,327 patients with 
pneumococcal bacteremia were seen in our institution 
(1.25 episodes/1000 admissions per year). On average, 
S. pneumoniae represented 4.65 % of all bacterial species 
isolated from blood cultures. Two hundred and sixty 
patients, evaluated by members of the Division of Infect- 
ious Diseases, constitute the population reviewed in the 
present report. Patients with AIDS were intentionally 
excluded from analysis. 
Sixty-nine (26.53%) patients were immunocom- 
promised hosts, based on strict case definitions (Table 1). 
Hematologic neoplasia (46.3%) followed by solid 
neoplasia (28.9%), corticosteroid therapy (14.4%) and 
collagen vascular disease (8.6%) were the most common 
underlying conditions leading to immunosuppression. 
A comparison of epidemiologic and clinical 
manifestations between immunocompromised and non- 
immunocompromised patients (Table 2) did not show 
differences in clinical presentation, presence of fever or 
obtundation, type of lung involvement, frequency of 
primary bacteremia, or meningitis. Immunocompromised 
patients more frequently had leukopenia or were unable 
to develop leukocytosis than controls (55% versus 26%, 
P=O.OOOl), had anemia (57% versus 19%, P=O.OOOl), 
and elevated concentrations of serum creatinine (39% 
versus 25 %, P= 0.02). Septic shock was significantly more 
frequent in immunocompromised patients (28% versus 
14%, P=O.Ol). Immunocompromised patients developed 
the infection while hospitalized for the treatment of the 
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Table 1. Underlying diseases in 69 immunocompromised 
patients with Streptococcus pneumoniae bacteremia 
Underlying disease 
Hematologic neoplasia 
Multiple myeloma 
Lymphoma 
Acute leukemia 
Chronic lymphocytic leukemia 
Macroglobulinemia 
Solid tumors 
Gastrointestinal 
Lung 
Breast 
Liver 
Other tumors 
Corticosteroid therapy 
Chronic bronchitis 
Idiopathic thrombocytopenic purpura 
Other conditions 
Collagen vascular disease 
Rheumatoid arthritis 
Cryoglobulinemia 
SLE 
Polyarteritis 
Agammaglobulinemia 
SLE, systemic lupus etythematosus. 
No. (%) 
32 (46.3) 
12 (17.3) 
9 (13) 
4 (5.7) 
4 (5.7) 
3 (4.3) 
20 (28.9) 
5 (7.2) 
5 (7.2) 
3 (4.3) 
2 (2.8) 
5 (7.2) 
10 (14.4) 
5 (7.2) 
2 (2.8) 
3 (4.3) 
6 (8.6) 
3 (4.3) 
1 
1 
1 
1 
underlying disease more frequently than patients in 
the control group (34.7% versus 6.8%, P<O.OOOl). All 
the cases were sporadic and unrelated to each other. 
In non-immunocompromised patients, pneumococcal 
bacteremia was basically a community-acquired infection 
(93.7% versus 65.2%, P~O.0001). 
Penicillin resistance was more frequently found in 
the isolates from immunocompromised patients (21 of 
56 versus 30 of 150, P=O.O09). This resistance was 
intermediate in 13 isolates (61.9%) and high level in 8 
(38.09%). We did not find differences in the prevalence 
of high-level resistance to penicillin between the groups 
(8/2lversus 10/30, P=O.77). 
The overall mortality and associated mortality 
(Table 3) were greater but not significantly different in 
both groups (33.3% versus 22.5%, P=O.O7, and 28.9% 
versus 20.9%, P=O.7, respectively). The risk factors 
associated with mortality (Table 4) in the multivariate 
analysis for the entire group of patients were: multilobar 
pneumonia (OR 15.7; 95% CI 6.00-41.30; P<O.OOl); 
inadequate therapy (OR 12.20; 95% CI 4.10-37.20; 
P<O.OOl); obtundation (OR 5.80; 95% CI 2.20-15.00; 
P<O.OOl); and hospital-acquired bacteremia (OR 4.80; 
Table 2. Clinical findings and outcome of immunocompromised patients with pneumococcal bacteremia and comparison with a 
group of non-immunocompromised patients 
Variable 
lmmunocompromised 
patients, 69 (%) 
Non-immunocompromised 
patients, 191 (%) P-value 
Mean age 
Male 
Female 
Acquisition 
Community 
Nosocomial 
Other underlying diseases 
Liver disease 
Diabetes mellitus 
Chronic lung disease 
Cardiomyopathy 
Clinical findings 
Fever 
Obtundation 
Leukocyte count < 11 OOO/mm 
Hemoglobin cl 1 g/dL 
Creatinine serum levels > 1.3 mg/dL 
Pneumonia 
Multilobar pneumonia 
Pleural effusion 
Primary bacteremia 
Meningitis 
Peritonitis 
Septic shock 
DIC and/or respiratory distress 
Strains resistant to penicillin 
64k15 
41 (59.4) 
28 (40.5) 
45 (65.2) 
24 (34.7) 
11 (15.9) 
5 (7.2) 
11 (15.9) 
15 (21.7) 
59 (85.5) 
17 (24.6) 
38 (55) 
39 (56.5) 
27 (39.1) 
58 (84) 
12 (17.3) 
13 (18.8) 
8 (11.5) 
3 (4.3) 
1 (1.4) 
19 (27.5) 
8 (11.5) 
21/56a (37.5) 
62217 
112 (58.6) 
79 (41.3) 
0.3 
0.9 
0.9 
178 (93.1) 0.0001 
13 (6.8) 0.0001 
31 (16.2) 0.95 
26 (13.6) 0.16 
53 (27.7) 0.05 
47 (24.6) 0.62 
177 (92.6) 0.078 
53 (27.7) 0.62 
50 (26.1) 0.0001 
36 (18.8) 0.0001 
48 (25.1) 0.02 
161 (84.2) 0.96 
41 (21.4) 0.47 
50 (26.1) 0.22 
10 (5.2) 0.09 
14 (7.3) 0.5 
4 (2) f 
27 (14.1) 0.01 
13 (6.8) 0.2 
30/150a(20) 0.0096 
“No. of strains tested. DIC, disseminated intravascular coagulation. 
Table 3. Mortality associated with pneumococcal bacteremia in immunocompromised patients 
lmmunocompromised Non-immunocompromised 
patients, no. (“/o) patients, no. (%) 
Overall mortality 23 (33.3) 43 (22.5) 
Related mortality 20 (28.9) 40 (20.9) 
P-value 
0.07 
0.7 
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Table 4. Risk factors for mortality in patients with pneumo- 
coccal bacteremia 
Variable Odds ratio (95% Cl) P-value 
Multilobar pneumoniaa 
Inappropriate therapy 
Obtundation 
Hospital-acquired 
15.7 (6.00-41.30) <O.OOl 
12.2 (4.10-37.20) 10.001 
5.8 (2.20-15.00) <O.OOl 
bacteremia 4.8 (1.00-14.60) <0.006 
aMultilobar pneumonia was associated with an increased risk of 
mortality in immunocompromised hosts (OR 7.90; 95% Cl: 4.10-15.35; 
P<O.OOl). 
95% CT 1.00-14.60; P<O.O06). Only multilobar pneu- 
monia was significantly associated with mortality in 
immunocompromised patients (OR 7.9; 95% CI 4.10- 
15.35; P<O.OOl). 
Only the patients with acute leukemia and lym- 
phoma had a significantly higher mortality rate related 
to pneumococcal infection when they were compared 
with the group of non-immunocompromised patients: 7 
of 13 (53.8%) patients died (P=O.O5). An analysis of 
these patients (Table 5) showed that six of the seven 
who died were neutropenic patients empirically treated 
with a combination of ceftazidime and amikacin. Five 
isolates from these patients were resistant to penicillin 
(MICs from 0.5 to 2 FglmL), and six were resistant to 
ceftazidime (MICs from 4 to -32 FglmL). Most patients 
followed a downhill course and died with fulminant 
septic shock within the first 3 days after the onset of 
symptoms. In four cases, vancomycin or imipenem was 
added to the initial therapy after the results of blood 
cultures were reported, but they also died. None of the 
six patients who survived pneumococcal infection were 
neutropenic, and all were empirically treated with anti- 
biotics such as cefotaxime, cefepime or vancomycin, 
which were active in vitro against the isolates. 
DISCUSSION 
A normal constituent of the human upper respiratory 
microbial flora, S. pneumoniae also produces respiratory 
infections that progress to invasive disease at high rates 
in specific risk groups. A combination of genetic and 
environmental elements with defects in host response to 
microbial invasion contributes to the increased rates of 
pneumococcal disease in immunocompromomised 
hosts.6,8 In our hospital, much of the burden of pneumo- 
coccal infection was attributable to a variety of 
immunosuppressive conditions. Twenty-six per cent of 
patients with pneumococcal bacteremia seen over a 
Table 5. Clinical findings, treatment and outcome of patients with acute leukemia and lymphoma who developed pneumococcal 
bacteremia 
Agel Underlying Clinical MIC (FglmL) 
Antimicrobial therapy 
Patient sex condition findings Acquisition PENICFZ Empirical Definitive Outcome 
la 47/M AML 
2a 60/M 
3 18/F 
4a 76/M 
5a 42/M 
6 58/F 
7 38/F 
8 73/F 
9a 
10a 
11 
12a 
13 
68/M 
62/M 
81/F 
78/M 
71/M 
AML 
ALL 
AML 
Hodgkin’s 
disease 
T-cell 
lymphoma 
Hodgkin’s 
disease 
MALT 
lymphoma 
Non-Hodgkin’s 
lymphoma 
Non-Hodgkin’s 
lymphoma 
Lymphocytic 
lymphoma 
Bone marrow 
transplant 
Burkitt’s 
lymphoma 
Multilobar 
pneumonia 
Multilobar 
pneumonia 
Pneumonia 
Multilobar 
pneumonia 
Multilobar 
pneumonia 
Pneumonia 
Primary 
bacteremia 
Pneumonia 
Multilobar 
pneumonia 
Multilobar 
pneumonia 
Pneumonia 
Multilobar 
pneumonia 
Primary 
bacteremia 
Nosocomial l/32 
Nosocomial 0.514 
Community 0.0610.5 
Nosocomial 2132 
Nosocomial 
Community 
Community 
Community 
Nosocomial 
Nosocomial 
Community 
Nosocomial 
Community 
O.O6/ND 
O.O6/ND 
O.O6/ND 
O.l/ND 
l/16 
0.518 
ND 
0.214 
O.O6/ND 
CFZ+AMK 
CFZ+AMK 
CFX+AMK 
CFZ+AMK 
IMP+AMK 
CFX+GEN 
VAN+AMK 
CFM 
CFZ+AMK 
CFZ+AMK 
CFX 
CFZ+AMK 
VAN+AMK 
Died, 2d 
Died, 2d 
Cured 
VAN Died, 4d 
Died, 3d 
Cured 
Cured 
Cured 
VAN Died, 5d 
IMP Died, 3d 
Cured 
VAN 
CFX 
Died, 9d 
Cured 
aPatients with neutropenia <50o 9ranu~Pc~es/~~3; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; MIC, minimal inhibitory 
concentration; PEN. penicillin; CFZ. ceftazidime; CFX, cefotaxime; CFM, cefepime; IMP, imipenem; AMK, amikacin; GEN, gentamicin; “AN, vancomycin; 
d. day of hospitalization; ND, not done. 
50 International Journal of Infectious Diseases I Volume 7, Number 1,2003 
period of 18 years were immunocompromised hosts with 
hematologic neoplasia or solid cancers, or were under- 
going corticosteroid therapy for to a variety of conditions. 
Some studies dealing with pneumococcal infection 
in patients with cancer have been published pre- 
viously.15,16 In addition, pneumococcal bacteremia in 
neutropenic patients with cancer was the subject of a 
recent report.i7 However, none of these studies provides 
data regarding the most relevant clinical aspects of the 
infection in immunocompromised patients. 
The clinical manifestations of pneumococcemia in 
immunocompromised patients were similar to those 
found in immunocompetent patients with common 
chronic disorders such as obstructive lung disease, 
cirrhosis of the liver, or diabetes mellitus. Although septic 
shock was more frequently found in immunocom- 
promised hosts, the mortality related to pneumoccoccal 
infection was not significantly different from that 
observed in the control group. Similar rates of mortality 
have been found by others.‘6,‘7 
Two aspects of pneumococcemia in immunocom- 
promised patients deserve special mention. 
First, in this group of patients, pneumococcal 
bacteremia frequently developed during hospitalization 
for the treatment of the underlying disease, and so, 
according to the CDC criteria, it may be regarded as a 
hospital-acquired infection. l4 In other series of pneumo- 
coccal bacteremia, the infection was hospital-acquired in 
5-58% of patients. 5~18.19 However, only in recent years 
has there been increasing interest in the role of S. 
pneumoniae as a nosocomial pathogen.20 Person-to- 
person spread can cause either sporadic cases or hospital 
outbreaks, primarily in younger children and the 
elderly,4,21 and patients with chronic bronchitis could be 
particularly important in the transmission of pneumo- 
cocci.21 The higher mortality rate of patients with 
hospital-acquired pneumococcal bacteremia observed in 
this study should encourage research on the better 
definition of risk factors and prevention. 
Second, more than one-third of pneumococcal strains 
isolated from immunocompromised patients were 
moderately susceptible or resistant to penicillin. This 
finding is not entirely unexpected, because previous 
therapy with p-lactam antibiotics and previous hospital- 
ization, both of which are risk factors for the acquisition 
of penicillin-resistant pneumococci, are also frequently 
found in these patients. 5,22,23 In addition, the presence of 
an immunosuppressive disorder has been associated 
with penicillin-resistant pneumococcal infection.24 
The prevalence of multiresistant S. pneumoniae is 
increasing worldwide, and the problem seems to be 
worsening in the USA also. 25 Management of penicillin- 
resistant pneumococcal infections poses serious thera- 
peutic difficulties. 26 Nevertheless, the impact of penicillin 
susceptibility on the outcome of patients with pneumo- 
coccal bacteremia has not been entirely ascertained. 
Previous reports have documented both a lack of 
association and an increased risk of mortality in patients 
with pneumococcal pneumonia caused by penicillin- 
resistant strains.5,23,27-29 This disparity may be a con- 
sequence of the currently accepted penicillin breakpoints 
for resistant pneumococccal isolates, which were estab- 
lished taking into account the penicillin concentrations 
attained in the cerebrospinal fluid of patients treated for 
meningitis.“,‘” 
Most evidence now indicates that standard treatment 
with p-lactam antibiotics is effective against pneumo- 
coccal pneumonia caused by strains with penicillin MICs 
no greater than 1 mg/L.5.27 In addition, pharmacokinetic 
and pharmacodynamic studies suggest that free-drug 
concentrations above the MIC for more than 40-50% 
of the dosing interval-which can be easily achieved 
during standard therapy with p-lactams-is the critical 
determinant of success.30,31 For these reasons, a working 
group has recently provided recommendations and new 
penicillin breakpoints for the management of pneumo- 
coccal pneumonia and the surveillance of drug-resistant 
S. pneumoniae.32 
In our series, inadequate treatment was associated 
with an increased risk of mortality in the multivariate 
analysis. However, this observation must be interpreted 
with some caution, due to the retrospective character of 
the study. In addition, because some patients followed a 
fulminant course and died within the first 24 h without 
receiving effective therapy, the role of inadequate 
prescription in the outcome is also difficult to assess. As 
shown by Austrian and Gold 38 years ago, some patients 
with pneumococcal pneumonia who were very sick on 
admission did not survive the infection, despite penicillin 
therapy, as a result of having passed the physiologic 
point of no return before such therapy was initiated.33 
Patients with acute leukemia and lymphoma may 
represent a subset of immunocompromised patients in 
whom inadequate therapy could be of great importance 
in determining an increased rate of mortality. Previous 
studies have estimated the mortality associated with 
pneumococcal bacteremia in patients with cancer and 
neutropenia who did not receive adequate treatment 
to be 75-100%.16~17 We identified a group of seven 
neutropenic patients with pneumococcemia who were 
treated with ceftazidime plus amikacin, a combination 
commonly given as empirical therapy for febrile episodes 
in neutropenic cancer patients, and who followed a 
downhill course and died. Although we believe that 
neutropenia was of paramount importance in the fatal 
outcome of these patients, six of the seven isolates from 
these patients were ceftazidime-resistant pneumococci, 
and so these patients were not effectively treated with 
antimicrobials during the first hours of hospitalization. 
The failure of vancomycin and imipenem treatment 
administered after the identification of the causative 
agent from the bloodstream suggests that early treat- 
ment may be critical in order to improve the prognosis 
of pneumococcal bacteremia in neutropenic patients. 
Penicillin-resistant pneumococci also show varying 
degrees of diminished susceptibility or resistance to all 
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p-lactam antibiotics. 34 Ceftazidime exhibits particularly 
weak activity against S. pneumoniae, and even less activity 
against penicillin-resistant strains.35 For this reason, 
we believe that immunocompromised and neutropenic 
patients who develop pneumonia should be treated with 
drugs active against resistant pneumococci, irrespective 
of the setting in which the infection develops. Broad- 
spectrum antibiotics such as cefepime or imipenem 
should be considered the first-choice drugs in this 
situation. 
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